A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01550926 |
Recruitment Status :
Completed
First Posted : March 12, 2012
Last Update Posted : January 28, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Overweight | Drug: 120 mg orlistat Drug: 60 mg orlistat Drug: orlistat experimental dose | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 48 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Official Title: | A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms |
Study Start Date : | February 2009 |
Actual Primary Completion Date : | March 2009 |
Actual Study Completion Date : | March 2009 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Arm 1
60 mg orlistat
|
Drug: 60 mg orlistat
60 mg orlistat |
Active Comparator: Arm 2
120 mg orlistat (2 X 60 mg capsules)
|
Drug: 120 mg orlistat
2 X60 mg capsule |
Experimental: Arm 3
orlistat experimental formulation
|
Drug: orlistat experimental dose
experimental |
- Fecal fat excretion [ Time Frame: 9 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- age: 18-60 years
- Body Mass Index: 25-33
Exclusion Criteria:
- gastrointestinal disease
- organ transplant
- HIV, hepatitis B or C
- food allergies
- alcohol or other substance abuse
- smoking

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01550926
United Kingdom | |
MDS Pharma Services | |
Belfast, N. Ireland, United Kingdom, BT9 6AD |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT01550926 |
Other Study ID Numbers: |
W3680604 |
First Posted: | March 12, 2012 Key Record Dates |
Last Update Posted: | January 28, 2013 |
Last Verified: | April 2012 |
orlistat overweight bioequivalence |
Overweight Body Weight Orlistat Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Anti-Obesity Agents Lipid Regulating Agents |